Real-world patient outcomes with Blinatumomab and Inotuzumab in adult relapsed/refractory B-cell acute lymphoblastic leukemia: a retrospective analysis from two Romanian oncology centers
Our findings emphasize the need for individualized treatment selection, rational immunotherapy sequencing, and the development of predictive biomarkers to optimize outcomes and minimize toxicity. Further studies are needed to refine therapeutic algorithms and define such prognostic biomarkers, particularly in underfunded healthcare systems.
Authors
- Manuela Ciocoiu (ORCID: https://orcid.org/0000-0002-9240-2175)
- Mihaela Mențel (ORCID: https://orcid.org/0000-0002-0878-5055)
- Vlad Andrei Cianga (ORCID: https://orcid.org/0000-0003-3215-2562)
- Ion Antohe (ORCID: https://orcid.org/0000-0002-2026-9336)
- Iuliu Cristian Ivanov (ORCID: https://orcid.org/0000-0001-5372-9901)
- Amalia Titieanu
- Alina Tănase (ORCID: https://orcid.org/0000-0003-3075-499X)
- Mihaela Zlei (ORCID: https://orcid.org/0000-0002-6865-8883)
- Angela Smaranda DASCALESCU (ORCID: https://orcid.org/0000-0001-5388-1583)
- Loredana Dragoş
- Anamaria Bancos (ORCID: https://orcid.org/0000-0001-6475-9866)
- Cosmin Minciună
- Ciprian Tomuleasa (ORCID: https://orcid.org/0000-0002-5770-7811)
- Catalin Danaı̈la
Institutions
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Grigore T. Popa University of Medicine and Pharmacy (RO)
- Institutul Regional de Oncologie (RO)
- Institute of Oncology Prof. Dr. Ion Chiricuta (RO)
- Institutul Clinic Fundeni (RO)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-12-10
- DOI
- https://doi.org/10.3389/fphar.2025.1684382
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministerul Cercetării, Inovării şi Digitalizării
- European Commission
- HORIZON EUROPE Framework Programme